

This Week's **TOP** **Industry** **NEWS**

Provided as a service to DCAT member companies each Friday.

Dear Members: As a DCAT member service, we will begin delivering you the week's *Top Industry News* each Friday to help ensure our members never have to miss the most important stories impacting the global pharmaceutical manufacturing industry.

BUSY WEEK? Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*

1. Allergan, Pfizer in Preliminary Talks About a Potential Transaction

A mega deal may be in the offering as both companies have confirmed that they are in preliminary discussions. The talks follow the close of the \$70 billion deal combining Allergan and Actavis and Allergan's subsequent decision to divest its generics business for Teva for \$40.5 billion. [Read More](#)

2. FTC OKs Mylan's Proposed Takeover of Perrigo

Mylan took another step in its takeover bid for Perrigo with the US FTC clearing the deal, subject to Mylan divesting select generic products. But the biggest hurdle remains with Perrigo shareholders voting on the transaction, which the company's board has thus far rejected, later this month. [Read More](#)

3. Sanofi Sets Long-Term Growth Plan: Plans Costs Savings of \$1.6 Billion

Sanofi has outlined the company's strategic roadmap for the period 2015-2020, which includes exploring strategic options for its animal health and European generics businesses. It is continuing a plan to simplify its global organization to achieve cost savings of EUR 1.5 billion (\$1.6 billion) by 2018, which includes aligning its manufacturing network to a growing biologics portfolio. [Read More](#)

4. Sanofi, Hanmi Form \$4.2 Billion Diabetes Pact

Sanofi and Hanmi Pharmaceutical Co., a Korea-based pharmaceutical company, have formed a worldwide license agreement valued up to EUR 3.9 billion (\$4.2 billion) to develop a portfolio of experimental, long-acting diabetes treatments. [Read More](#)

5. Shire to Acquire Dyax for \$5.9 Billion

In a move to strengthen its rare-disease product portfolio, Shire has agreed to acquire Dyax Corp., a biopharmaceutical company developing plasma kallikrein (pKal) inhibitors for treating hereditary angioedema, for \$5.9 billion. [Read More](#)

6. BMS To Acquire Cardioxyl in \$2 Billion-Plus Deal

Bristol-Myers Squibb has agreed to acquire Cardioxyl, a privately held biotechnology company developing treatments for cardiovascular disease, in a deal valued up to more than \$2 billion. [Read More](#)

7. Novo Nordisk Breaks Ground on New Manufacturing Facility

Novo Nordisk is investing 2.1 billion Danish kroner (\$306 million) in a new 10,300-square-meter facility in Hillerød, Denmark, for producing drugs for diabetes and obesity. [Read More](#)

8. [Eli Lilly To Expand R&D HQ](#)

Eli Lilly and Company plans to expand its global R&D headquarters in Indianapolis, Indiana, through a \$70 million investment, part of Lilly's continued growth of its Indianapolis footprint, which included a \$400 million expansion initiated in 2013 to increase its insulin manufacturing capacity. [Read More](#)

9. [Pfizer, GSK Partner in Solid Dosage Continuous Manufacturing](#)

Pfizer has formed a multi-year collaboration with GlaxoSmithKline for equipment design, based on Pfizer's existing portable, continuous, miniature and modular prototype for oral solid dose pharmaceutical development and manufacturing. [Read More](#)

10. [Saltigo Plans \\$65 Million Expansion](#)

Saltigo is investing EUR 60 million (\$65 million) to expand its production facilities in Leverkusen, Germany, the single largest investment in Saltigo since it was founded as a fine chemicals company in 2006. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have an enjoyable weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



Drug, Chemical & Associated Technologies Association

The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, member-supported business development association for the global pharmaceutical development manufacturing industry. We are committed to providing programs, events and services that help our members expand their network of customers, suppliers and colleagues in the industry.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

[Forward this email](#)



This email was sent to esanders@dcat.org by dcatnews@dcat.org | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691